摘要
目的:研究不同剂量贝那普利对IgA肾病患者蛋白尿及病理类型的影响。方法:选取IgA肾病患者120例,随即分为A组60例,即服用贝那普利10mg,B组60例即服用贝那普利20mg组,观察两组治疗前、后的各项指标变化;两组按WHO分为Ⅰ～Ⅴ级,并在治疗2年后重复肾穿,设为自身对照。结果:比较发现两组治疗后尿蛋白均较治疗前明显下降,相差具有统计学意义(P<0.05);但B组治疗后较A降低更明显,差异较显著(P<0.05);自身对照比较发现,治疗后两组病理类型较治疗前明显减轻,但20mg组较10mg组比较差异不显著(P>0.05)。结论:贝那普利可以降低蛋白尿,并且贝那普利20mg组较10mg作用更明显,对病理类型影响不大。
Objective：To observe the influence of different dosage Benazepril on proteinuria and the pathology type of the IgA nephropathy（IgAN）.Methods：120 IgAN patients were randomly separated into two groups： 10mg group（Benazepril 10mg/d）and 20mg group（Benazepril 20mg/d）.To observe the therapy change and the influence in the 2 years of renal biopsy,two groups were seperated into Ⅰ~Ⅴ types in order to WHO.Results：The urine protein excretion had obviously decreased in two groups,and it was decreased more and the same side reaction observed in 20mg group.Conclusion：Benazepril can reduce urine protein excretion but it was no influence in dosage Benazepril.
出处
《医学理论与实践》
2012年第21期2607-2608,共2页
The Journal of Medical Theory and Practice
